TEV-56286

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

20 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

1

Rifadin

Sanofi

Approved

—2

Northera

Lundbeck

Approved

—3

Sudafed

KKenvue Brands

Approved

—4

Rilutek

AAzurity Pharmaceuticals

Approved

—5

Lu AF95245

Lundbeck

Phase 2

16

Foralumab

TTiziana Life Sciences LTD

Phase 2

17

Bendopa

MMerz North America, Inc.

Preclinical

18

TEV-56286

Teva

Phase 2

29

ATH434

AAlterity Therapeutics

Phase 2

210

Human Dopaminergic Progenitor Cells

IiRegene Therapeutics Co., Ltd.

Phase 1

1Show 3 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple System Atrophy2 trials

An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Recruiting·Teva·Phase 2·NCT07197866·200 enrolled

A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)

Recruiting·Teva·Phase 2·NCT06568237·350 enrolled

ESS1 trial

A Study to Assess New Formulations of TEV-56286

Completed·Teva·Phase 1·NCT06911567·47 enrolled

Unspecified2 trials

A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Escalating Dose Trial in Healthy Participants to Assess Pharmacokinetics, Safety, and Tolerability of TEV-56286 at Clinical and Supratherapeutic Doses

Recruiting·Teva·Phase 1·NCT07674940·69 enrolled

A Phase 1 Open-Label Mass Balance Clinical Trial to Investigate the Absorption, Metabolism, and Excretion of Single Oral Administration of [14C]-TEV-56286 Following Multiple Oral Administrations of Nonlabeled TEV-56286 to Healthy Male Participants

Completed·Teva·Phase 1·NCT06627231·8 enrolled

Details

Drug Info

Related News